DeRycke Melissa S, Andersen John D, Harrington Katherine M, Pambuccian Stefan E, Kalloger Steve E, Boylan Kristin L M, Argenta Peter A, Skubitz Amy P N
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA.
Am J Clin Pathol. 2009 Dec;132(6):846-56. doi: 10.1309/AJCPTK87EMMIKPFS.
We sought to investigate the expression levels of S100A1 in ovarian cancer cell lines and tissues to correlate S100A1 with subtype, stage, grade, and relapse-free survival. S100A1 messenger RNA and protein were up-regulated in ovarian cancer cell lines and tumors compared with normal ovarian cell lines and tissues by gene microarray analysis, reverse transcriptase-polymerase chain reaction, quantitative reverse transcriptase-polymerase chain reaction, and Western immunoblotting. In the study, 63.7% of serous, 21.2% of clear cell, 11.2% of endometrioid, and 3% of mucinous ovarian (1/31) cancers were S100A1+ by immunohistochemical staining of tissue microarrays (n = 500). S100A1 expression increased with increasing Silverberg grade but not stage in serous tumors. Endometrial tissue microarrays (n = 127) were 9.4% S100A1+; no correlation with stage or grade and S100A1 was found. In the endometrioid subtype of ovarian and endometrial cancers, relapse-free survival was decreased for patients with S100A1+ tumors. These data suggest that S100A1 is a marker for poor prognosis of endometrioid subtypes of cancer.
我们试图研究S100A1在卵巢癌细胞系和组织中的表达水平，以将S100A1与亚型、分期、分级及无复发生存率相关联。通过基因微阵列分析、逆转录-聚合酶链反应、定量逆转录-聚合酶链反应及蛋白质免疫印迹法，与正常卵巢细胞系和组织相比，S100A1信使核糖核酸和蛋白质在卵巢癌细胞系及肿瘤中上调。在该研究中，通过组织芯片（n = 500）的免疫组织化学染色，63.7%的浆液性、21.2%的透明细胞性、11.2%的子宫内膜样及3%的黏液性卵巢癌（1/31）为S100A1阳性。在浆液性肿瘤中，S100A1表达随Silverberg分级增加而升高，但与分期无关。子宫内膜组织芯片（n = 127）中9.4%为S100A1阳性；未发现分期或分级与S100A1之间存在相关性。在卵巢癌和子宫内膜癌的子宫内膜样亚型中，S100A1阳性肿瘤患者的无复发生存率降低。这些数据表明，S100A1是癌症子宫内膜样亚型预后不良的一个标志物。
